A detailed history of Nisa Investment Advisors, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 917 shares of BEAM stock, worth $26,207. This represents 0.0% of its overall portfolio holdings.

Number of Shares
917
Previous 724 26.66%
Holding current value
$26,207
Previous $16,000 37.5%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$22.57 - $33.14 $4,356 - $6,396
193 Added 26.66%
917 $22,000
Q2 2024

Jul 19, 2024

SELL
$21.22 - $32.66 $1,039 - $1,600
-49 Reduced 6.34%
724 $16,000
Q1 2024

May 01, 2024

BUY
$23.46 - $45.07 $2,862 - $5,498
122 Added 18.74%
773 $25,000
Q4 2023

Jan 25, 2024

SELL
$17.69 - $30.76 $47,073 - $81,852
-2,661 Reduced 80.34%
651 $17,000
Q3 2023

Nov 02, 2023

BUY
$23.01 - $32.46 $31,385 - $44,275
1,364 Added 70.02%
3,312 $79,000
Q2 2023

Aug 11, 2023

BUY
$29.32 - $35.99 $5,658 - $6,946
193 Added 11.0%
1,948 $62,000
Q1 2023

May 02, 2023

BUY
$30.15 - $48.79 $422 - $683
14 Added 0.8%
1,755 $54,000
Q4 2022

Feb 02, 2023

BUY
$36.73 - $51.6 $10,541 - $14,809
287 Added 19.74%
1,741 $68,000
Q3 2022

Nov 07, 2022

BUY
$39.79 - $70.31 $13,687 - $24,186
344 Added 30.99%
1,454 $64,000
Q2 2022

Aug 03, 2022

SELL
$29.86 - $62.36 $8,360 - $17,460
-280 Reduced 20.14%
1,110 $43,000
Q1 2022

Apr 29, 2022

SELL
$53.73 - $82.16 $6,447 - $9,859
-120 Reduced 7.95%
1,390 $80,000
Q4 2021

Feb 03, 2022

SELL
$68.02 - $99.06 $346,221 - $504,215
-5,090 Reduced 77.12%
1,510 $105,000
Q3 2021

Oct 18, 2021

BUY
$84.37 - $133.6 $404,976 - $641,280
4,800 Added 266.67%
6,600 $574,000
Q4 2020

Jan 25, 2021

BUY
$22.24 - $95.63 $40,032 - $172,134
1,800 New
1,800 $147,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $2.01B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.